Rituximab Plus High-dose Chemotherapy With Autologous Stem Cell Support for Non-Hodgkin's Lymphoma
Combination chemotherapy is the standard treatment as initial therapy for advanced stage
aggressive Non-Hodgkin's lymphoma (NHL). Standard chemotherapy cures less than 40% of
patients. When patients relapse, they may be eligible to receive high-dose chemotherapy
with autologous stem cell support. Multiple studies have shown the value of high-dose
chemotherapy, with increased disease-free survival and overall survival, when compared with
second-line conventional chemotherapy. Unfortunately high-dose chemotherapy is curative in
less than half the patients who receive it, and other treatment strategies are needed to
improve the cure rate.
Another treatment option called immunotherapy is being tested in lymphoma patients.
Immunotherapy involves attempts to use the immune system or products of the immune system to
fight lymphoma. For example, NHL cells have a protein called CD20 on their surface.
Rituximab is an antibody directed against the CD20 protein, which may result in the death of
the lymphoma cell. Patients in this study will receive Rituximab to see if it is a safe
treatment option for NHL patients.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Assess safety and toxicity after rituximab and high-dose chemotherapy
Raymond J. Hutchinson, MD
University of Michigan
United States: Institutional Review Board
|The University of Michigan||Ann Arbor, Michigan 48109|